FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.681,61 +760,17 (+1,29%)
Cingulate Inc. (CING)
| Chiusura precedente | 0,8653 |
| Aperto | 0,8684 |
| Denaro | 0,8484 x 100 |
| Lettera | 0,9216 x 100 |
| Min-Max giorno | 0,8400 - 0,9299 |
| Intervallo di 52 settimane | 0,7500 - 23,4000 |
| Volume | |
| Media Volume | 311.646 |
| Capitalizzazione | 5,322M |
| Beta (5 anni mensile) | -0,96 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -26,0000 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 21,50 |
GlobeNewswireCingulate Inc. to Present at the LD Micro Main Event XVI
Presentation on Wednesday, October 4th at 02:30 PM PTKANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that Chairman & CEO, Shane J. Schaffer, will be presenting a company overview at the 16th annual Main Event on Wednesday, October 4th at 02:30 PM PT at
- GlobeNewswire
Cingulate Announces Closing of $4.0 Million Public Offering
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the closing of its previously announced public offering of an aggregate of 6,925,208 shares of its common stock (or common stock equivalents in lieu ther
- GlobeNewswire
Cingulate Announces Pricing of $4.0 Million Public Offering
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the pricing of its public offering of an aggregate of 6,925,208 shares of its common stock (or common stock equivalents in lieu thereof), Series A warran
